2
项与 特立帕肽生物类似药(Stelis Biopharma Pvt Ltd.) 相关的临床试验A single center, randomized, double blind, 3-treatment, 3-period, single-dose, cross over, comparative Phase-1 study to evaluate pharmacokinetics, safety, tolerability, and pharmacodynamics (PK/PD) of Stelis Teriparatide [rh-PTH (1-34)] with Forsteo® and Forteo® (teriparatide, Eli Lilly) in healthy volunteers following subcutaneous single dose administration of 20 µg Teriparatide
A randomized, double blind, 2-treatment, 2-period, single-dose, cross over, comparative study to evaluate pharmacokinetics, safety and tolerability of Stelis Teriparatide [rh-PTH (1-34)] [teriparatide, Stelis Biopharma Pvt. Ltd., India] with ForsteoRegistered Trademark (teriparatide, Eli Lilly Nederland BV, Grootslag 1-5, NL-3991 RA Houten, The Netherlands) in healthy volunteers following subcutaneous administration of a single dose of 20 mcg Teriparatide
100 项与 特立帕肽生物类似药(Stelis Biopharma Pvt Ltd.) 相关的临床结果
100 项与 特立帕肽生物类似药(Stelis Biopharma Pvt Ltd.) 相关的转化医学
100 项与 特立帕肽生物类似药(Stelis Biopharma Pvt Ltd.) 相关的专利(医药)
100 项与 特立帕肽生物类似药(Stelis Biopharma Pvt Ltd.) 相关的药物交易